Proteoglycans and the extracellular matrix in amyloidosis

Amyloid

Volumn 4, Issue 2, 1997, Pages 121-134

  Magnus, Jeanette H ^a   Stenstad, Tore ^b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Alzheimer's disease; Amyloid; Extracellular matrix; Proteoglycans

Indexed keywords

EID: 1542528944     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506129708995282     Document Type: Article

References (132)

1. Cohen AS, Jones LA (1991). Amyloidosis (review). Curr Opin Rheumatol. 3, 125-138
2. Glenner GG (1980). Amyloid deposits and amyloidosis. The beta-fibrilloses (review). N Engl J Med. 302, 1283-1292 and 302, 1333-1343
3. Glenner GG (1980). Amyloid deposits and amyloidosis. The beta-fibrilloses (review). N Engl J Med. 302, 1283-1292 and 302, 1333-1343
4. Husby G, Araki S, Benditt EP, Benson MD, Cohen AS, Frangione B, Glenner GG, Natvig JB and Westermark P (1990) The 1990 guidelines for nomenclature and classification of amyloid and amyloidosis. In Natvig J, Forre Ø, Husby G et al, (eds.). Amyloid and amyloidosis, pp. 7-11. (Dordrecht: Kluwer Academic Publishers)
5. Puchtler H, Waldrop FS, Meloan SN (1985). A review of light, polarization and fluorescence microscopic methods for amyloid. Appl Pathol. 3, 5-17
6. Glenner GG, Ein D, Eanes ED, Bladen HA, Terry W, Page DL (1971). Creation of «amyloid» fibrils from Bence Jones proteins in vitro. Science. 174, 712-714
7. Westermark P (1992). The N-terminal segment of protein AA determines its fibrillogenic property. Biochem Biophys Res Commun. 182, 27-33
8. Skinner M, Cohen AS (1988). Amyloid P component. Methods Enzymol. 163, 523-536
9. Scott J E (1995). Extracellular matrix, supramolecular organisation and shape. J Anat 187, 259-269
10. Slater M (1996). Dynamic interactions of the extracellular matrix. Histol Histopathol 11, 175-180
11. Coutts JC and Gallagher JT (1995). Receptors for fibroblast growth factors. Immunol Cell Biol 73, 584-89
12. Raghow R (1994). The role of extracellular matrix in postinflammatory wound healing and fibrosis. FASEB J 8, 823-831
13. Labat-Robert J, Bihari-Varga M and Robert L (1990). Extracellular matrix. FEBS Lett 268, 386-393
14. Salmivarta M and Jalkanen M (1995). Syndecan family of cell surface proteoglycans: developmentally regulated reseptors for extracellular effector molecules. Experientia 51, 863-72
15. Nietfeld JJ (1993) Cytokines and proteoglycans. Experientia 49, 456-469
16. Jackson RL, Busch SJ and Cardin AD (1991). Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Phys Review 71, 481-539
17. Ruoslahti E (1988). Structure and biology of proteoglycans. Ann Rev Cell Biol 4, 229-255
18. Ruoslahti E and Yamaguchi Y (1991). Proteoglycans as modulators of growth factor activities. Cell 64, 867-869
19. Ruoslahti E (1989) Proteoglycans in cell regulation. J Biol Chem 264, 13369-13372
20. Kjellèn L and Lindahl U (1991). Proteoglycans: structures and interactions. Ann Rev Biochem 60, 443-475
21. Doege K J, Sasaki M, Kimura T and Yamada Y (1991). Complete coding sequence and deduced primary structure of the human cartilage large aggregating proteoglycan, aggrecan. J Biol Chem 266, 894-902
22. Margolis RK and Margolis RU (1994). Nervous tissue proteoglycans. Experientia 70, 144-177
23. Kresse H, Hausser H, Schöner E and Bittner K (1994). Biosynthesis and Interactions of small chondroitin/dermatan sulphate proteoglycans Eur J Clin Chem Clin Biochem 32, 259-64
24. Vogel KG, Trotter JA (1987). The effect of proteoglycans on the morphology of collagen fibrils formed in vitro. Coll Relat Res. 7, 105-114
25. Engvall E (1995). Structure and function of basement membranes. Int J Dev Biol 39, 781-87
26. Yurchenco PD and Schittny JC (1990) Molecular architecture of basement membranes. FASEB J 4, 1577-1590
27. Noonan DM, Hassell JR (1993). Perlecan, the large low-density proteoglycan of basement membranes: structure and variant forms. Kidney Int. 43, 53-60
28. Tsen G, Halfter W, Kröger S, Cole GJ (1995). Agrin is a heparan sulphate proteoglycan. J Biol Chem 270, 3392-3397
29. Iozzo Rv, Cohen IR, Grässel S, Murdoch AD (1994). The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302, 625-39
30. Doyle L (1988). Lardaceous disease: some early reports by British authors (1722-1879). J Royal Soc Med 81, 729-31
31. Hass G (1942). Studies on amyloid. II. The isolation of a polysaccharide from amyloid-bearing tissues. Arch Pathology 34, 92-105
32. Bassiouni M (1955). Studies on the acid polysaccharide of the with cells in rheumatic and other diseases showing its similarity to the acid polysaccharide of amyloid. Ann Rheum Dis 14, 288-92
33. Linker A, Hoffman P, Samson P and Meyer K (1958) Heparitin sulfate. Biochim Biophys Acta 29, 443-444
34. Cohen A. (1966). Preliminary chemical analysis of partially purified amyloid fibrils. Lab Invest 15, 66-83
35. Pras M, Nevo Z, Schubert M, Rotman J and Matalon R (1971). The significance of mucopolysaccharides in amyloid. J Histochem Cytochem 10, 443-448
36. Snow AD and Kisilevsky R (1985). Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis. A histochemical study. Lab Invest 53, 37-44
37. Snow AD, Willmer J and Kisilevsky R (1987). A close ultrastructural relationship between sulfated proteoglycans and AA amyloid fibrils. Lab Invest 57, 687-698
38. Snow AD, Kisilevsky, Stephens C and Anastassiades T (1987). Characterization of tissue and plasma glycosaminoglycans during experimental AA amyloidosis and acute inflammation. Lab Invest 56, 665-675
39. Snow AD and Wight TN (1989). Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol Aging 10, 481-497
40. Kisilevsky R, Lyon AW and Young ID (1992). A critical analysis of postulated pathogenetic mechanisms in amyloidogenesis. Crit Rev Clin Lab Sci 29, 59-82
41. Bitter T and Muir H (1966). Mucopolysaccharides of whole human spleens in generalized amyloidosis. J Clin Invest 45, 963-975
42. Linker A and Carney HC (1987). Presence and role of glycosaminoglycans in amyloidosis. Lab Invest 57, 297-305
43. Nelson SR, Lyon M, Gallagher JT, Johnson EA and Pepys MB (1991). Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. Biochem J 275, 67-73
44. Berenson GS, Dalferes ER, Ruiz H and Radhakrishnamurthy B (1969). Changes of acid mucopolysaccharides in the heart involved by amyloidosis. Am J Cardiol 24, 358-364
45. Magnus JH, Stenstad T, Kolset SO and Husby G (1991). Glycosaminoglycans in extracts of cardiac amyloid fibrils from familial amyloid cardiomyopathy of Danish origin related to variant transthyretin Met-111. Scand J Immunol 34, 63-69
46. Lindahl B, Eriksson L and Lindahl U (1995). Structure of heparan sulphate from human brain, with special regard to Alzheimer's disease. Biochem J 306, 177-184
47. Snow AD, Nochlin D, Sekiguchi R, Carlson SS (1996). Identification and immunolocalization of a new class of proteoglycan (keratan sulfate) to the neuritic plaques of Alzheimer's disease. Exp Neurol 138, 305-317
48. Lindahl B, Eriksson L, Spillmann D, Caterson B, Lindahl U (1996). Selective loss of cerebral keratan sulfate in Alzheimer's disease. J Biol Chem 271, 1691-1694
49. Niewold TA, Landeria JM, van den Heuvel LPWJ, Ultee A, Tooten PCJ and Veerkamp JH (1991). Characterisation of proteoglycans and glycosaminoglycans in bovine renal AA amyloidosis. Virchow Archiv B Cell Pathol 60, 321-328
50. Magnus JH (1991). Isolation and characterization of amyloid associated glycosaminoglycans and proteoglycans from human tissues. Thesis, University of Tromsø
51. Young ID, Willmer JP and Kisilevsky R (1989). The ultrastructural localization of sulfated proteoglycans is identical in the amyloids of Alzheimer's disease and AA, AL, senile cardiac and medullary carcinoma-associated amyloidosis. Acta Neuropathol 78, 202-209
52. Young ID, Ailles L, Narindrasorasak S, Tan R and Kisilevsky R (1992). Localization of the basement membrane heparan sulfate proteoglycan in islet amyloid deposits in type II diabetes mellitus. Arch Pathol Lab Med 116, 951-954
53. Snow AD, Mar H, Nochlin D, Kimata K, Kato M, Suzuki S, Hassell J and Wight TN (1988). The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am J Pathol 133, 456-463
54. Snow AD, Bramson R, Mar H, Wight Tna and Kisilevsky R (1991). A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. J Histochem Cytochem 39, 1321-1330
55. Ailles L, Kisilevsky R and Young ID (1993). Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis Lab Invest 69, 443-448
56. Stenstad T, Magnus JH, Husby G (1995). Characterization of proteoglycans associated with mouse splenic AA amyloidosis. Biochem J 303, 663-670
57. Magnus JH, Stenstad T and Husby G (1994). Proteoglycans, glycosaminoglycams and amyloid deposition. Baillière's Clin Rheumatol 8, 575-597
58. Perlmutter LS and Chui HC (1990). Microangiopathy, the vascular basement membrane and Alzheimer's disease: a review. Brain Res Bull 24, 677-686
59. Magnus, JH, Stenstad T, Husby G, and Kolset SO (1992). Isolation and partial characterization of heparan sulphate proteoglycans from human hepatic amyloid. Biochem J 288, 225-231
60. Buée L, Ding W, Delacourte A and Fillit H (1993). Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide. Brain Res 601, 154-163
61. Stenstad T, Magnus JH, Husby H, and Kolset SO (1993). Purification of amyloid-assoiciated heparan sulphate proteoglycans and galactosaminoglycan free chains from human tissues. Scand J Immunol 37, 227-235
62. Magnus JH, Kolset SO, Husby G (1991). High molecular weight glycosaminoglycans in AA type amyloid fibril extracts from human liver. Ann Rheum Dis 50, 562-66
63. Snow AD, Mar H, Nochlin D, Kresse H and Wight TN (1992) Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid-containin plaques and their distribution in neurofibrillary tangles in Alzheimer's disease. J Histochem Cytochem 40, 105-113
64. DeWitt, DA, Silver J, Canning DR and Perry G (1993). Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease. Exp Neurol 121, 149-152
65. Norling, B, Westermark GT, and Westermark P (1988). Immunohistochemical identification of heparan sulphate proteoglycan in secondary systemic amyloidosis. Clin Exp Immunol 73, 333-337
66. Lyon, AW, Narindrasorasak S, Young ID, Anastassiades T, Couchman JR, McCarthy KJ, and Kisilevsky R (1991). Codeposition of basement membrane components during the induction of murine splenic AA amyloid. Lab Invest 64, 785-790
67. Kawahara E, Shiroo M, Nakanishi I, and Migita S (1989). The role of fibronectin in the development of experimental amyloidosis. Am J Pathol 134, 1305-1314
68. Zanusso GL, Moretto G, Bonetti B, Monaco S and Rizzuto N (1992). Complement neoantigen and vitronectin are components of plaques in amyloid AL neuropathy. Ital J Neurol Sci 13, 493-499
69. Cohen AS (1994). Clinical aspects of amyloidosis, including related proteins and central nervous system amyloid. Curr Opin Rheumatol 6, 68-77
70. Ghiso J, Wisniewski T, Frangione B (1994). Unifying features of systemic and cerebral amyloidosis. Mol Neurobiol 8, 49-64
71. Multhaup G (1994). Identification and regulation of the high affinity binding of the Alzheimer's disease amyloid protein precursor (APP) to glycosaminoglycans. Biochimie 76, 304-311
72. Shioi J, Pangalos MN, Ripellino JA, Vassilacopoulou D, Mytilineou C, Margolis RU and Robakis NK (1995). The Alzheimer amyloid precursor proteoglycan (appican) is present in brain and is produced by astrocytes but not by neurons in primary neural cultures. J Biol Chem 270, 11839-11844
73. Pangalos MN, Efthimiopoulous S, Shioi J and Robakis NK (1995). The chondroitin sulfate attachment site of appican is formed bu splicing out exon 15 of the amyloid precursor gene. J Biol Chem 270, 10388-10391
74. Buée L, Hof PR, Bouras C, Delacourte A, Perl DP, Morrison JH and Fillit HM (1994). Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol (Berl) 87, 469-480
75. Snow AD, Kisilevsky R, Willmer J, Prusiner SB and DeArmond SJ (1989). Sulfated glycosaminoglycans in amyloid plaques of prion diseases. Neuropathologica 77, 337-342
76. Guiroy DC, Yanagihara R and Gajdusek DC (1991). Localization of amyloidogenic proteins and sulfated glycosaminoglycans in nontransmissible and transmissible amyloidoses. Acta Neuropathol (Berl) 82, 87-92
77. Jucker M, Walker LC, Schwarb P, Hengemihle J, Kuo H, Snow AD, Bamert F and Ingram DK (1994). Age-related deposition of glia-associated fibrillar material in brains of C56BL/6 mice. Neuroscience 60, 875-889
78. VanDuinen SG, Maat-Schierman MLC, Bruijn JA, Haan J and Roos RAC (1995). Cortical tissue of patients with hereditary cerebral hemorrhage with amyloidosis (Dutch)contains various extracellular matrix deposits. Lab Invest 73, 183-189
79. Snow AD, Sekiguchi RT, Nuchlin D, Kalaria RN and Kimata K (1994). Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. Am J Pathol 144, 337-347
80. vanGool D, David G, Lammens M, Baro F and Dom R (1993). Heparan sulfate expression patterns in the amyloid deposits of patients with Alzheimer's and Lewy body type dementia. Dementia 4, 308-314
81. Howard J and Pilkington GJ (1990). Antibodies to fibronectin bind to plaques and other structures in Alzheimer's disease and control brain. Neurosci Lett 118, 71-76
82. Perlmutter LS, Barron E, Saperia D and Chui HC (1991). Association between vascular basement membrane components and the lesions of Alzheimer's disease. J Neurosci Res 30, 673-681
83. Murtomaki S, Risteli J, Risteli L, Koivisto UM, Johansson S, Liesi P (1992). Laminin and its neurite outgrowth-promoting domain in the brain in Alzheimer's disease and Down's syndrome patients. J Neurosci Res 32, 261-273
84. Van der Wal EA, Gomez-Pinilla F, Cotman CW (1993). Transforming growth factor-beta 1 is in plaques in Alzheimer and Down pathologies. Neuroreport, 4(1): 69-72
85. Stopa EG, Gonzalez AM, Chorsky R, Corona RJ, Alvarez J, Bird ED, Baird A (1990). Basic fibroblast growth factor in Alzheimer's disease. Biochem Biophys Res Commun 171, 690-696
86. Brunden KR (1993). PH-dependent binding of synthetic beta-amyloid peptides to glycosaminoglycans. J Neurochem 61, 2147-2154
87. Multhaup G, Mechler H, Masters CL (1995). Characterization of the high affinity heparin binding site of the Alzheimer's disease βA4 amyloid precursor protein (APP) and its enhancement by zinc(II). J Mol Recognition 8, 247-257
88. Breen KC (1995). Heparin induction of the beta-amyloid precursor protein (AβPP) in a neural cell line is regulated by cell confluency state. Amyloid: Int J Exp Clin Invest 2, 17-21
89. Wong S, and Kisilevsky R (1990). Influence of sulphate ions on the structure of AA amyloid fibrils. Scand J Immunol 32, 225-232
90. Fraser PE, Nguyen JT, Chin DT, and Kirschner DA (1992). Effects of sulfate ions on Alzheimer β/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J Neurochem 59, 1531-1540
91. McCubbin, WD, Kay CM, Narindrasorasak S, and Kisilevsky R (1988). Circular-dichroism studies on two murine serum amyloid A proteins. Biochem J 156, 775-783
92. Snow AD, Kinsella MG, Parks E, Sekiguchi RT, Miller JD, Kimata K and Wight TN (1995). Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin and versican) to the beta-amyloid protein of Alzheimer's disease. Arch Biochem Biophys 320, 84-95
93. Narindrasorasak S, Altman RA, Gonzalez-DeWhitt P, Greenberg B and Kisilevsky R (1995). An interaction between basement membrane and Alzheimer's amyloid precursor proteins suggests a role in the pathogenesis of Alzheimer's disease. Lab Invest 72, 272-282
94. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG and Szarek WA (1995). Arresting amyloidosis in vivo using small-molecule an ionic sulphonates or sulphates: implications for Alzheimer's disease. Nature Med 1, 143-148
95. Priola SA and Caughey B (1994). Inhibition of scrapie-associated PrP accumulation. Mol Neurobiol 8, 113-120
96. Caughey B, Brown K, Raymond GJ, Katzenstein GE and Thresher W (1994). Binding of the protease-sensitive form of prion protein PrP to sulfated glycosaminoglycan and Congo red. J Virol 68, 2135-2141
97. Koo EH, Park L and Selkoe DJ (1993). Amyloid β-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. Proc Natl Acad Sci USA 90, 4748-4752
98. Small, DH, Nurcombe V, Clarris H, Beyreuther K and Masters CL (1993). The role of extracellular matrix in the processing of the amyloid protein precursor of Alzheimer's disease. Ann New York Acad Sci 695, 169-174
99. Monning U, Sandbrink R, Weidemann A, Banati RB, Masters CL and Beyreuther K (1995). Extracellular matriz influences the biogenesis of amyloid precursor protein in microglial cells. J Biol Chem 270, 7104-7110
100. Gupta-Bansal R, Frederickson RC and Brunden KR (1995). Proteoglycan-mediated inhibition of A beta proteolysis. A Potential cause of senile plaque accumulation. J Biol Chem 270, 18666-18671
101. Leveugle B and Fillit H (1994). Proteoglycans and the acute-phase response in Alzheimer's disease brain. Mol Neurobiol 9, 25-32
102. Oldberg A, Antonsson P, Hedbom E and Heinegard D (1990). Structure and function of extracellular matrix proteoglycans. Bio Soc Trans 18, 789-792
103. Stone AL (1977). Optical conformation of heparin and heparin complexes with cationic dyes, amines and protein models. Fed Proc 36, 101-106
104. Dyck RF, Lockwood CM, Kershaw M, McHugh N, Duance VC, Baltz ML and Pepys MB (1980). Amyloid P-component is a constituent of normal human glomerular basement membrane. J Exp Med 152, 1162-1174
105. Pepys MB, Dyck RF, deBeer FC, Skinner M and Cohen AS (1979). Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol 38, 284-293
106. Stenstad T, Magnus JH, Syse K and Husby G (1993). On the association between amyloid fibrils and glycosaminoglycans; possible interactive role of Ca2+ and amyloid P-component. Clin Exp Immunol 94, 189-195
107. Alizadeh-Khiavi K, Normand J, Chronopoulos S, Ali A and Ali-Khan Z (1992). Amyloid enhancing factor is associated with ubiquitin. Virch Arch A Pathol Anat 420, 139-148
108. Narindrasorasak S, Lowery D, Gonzalez-DeWhitt P, Poorman RA, Greenberg B and Kisilevsky R (1991). High affinity interactions between the Alzheimer's beta-amyloid precursor proteins and the basement membrane form of heparan sulfate proteoglycan. J Biol Chem 266, 12878-12883
109. Narindrasorasak S, Lowery DE, Altman RA, Gonzalez-DeWhitt PA, Greenberg BD and Kisilevsky R (1992). Characterization of high affinity binding between laminin and Alzheimer's disease amyloid precursor proteins. Lab Invest 67, 643-652
110. Preciado-Patt L, Hershkoviz R, Fridkin M, Lider O (1996). Serum amyloid A binds specific extracellular matrix glyco-proteins and induces the adhesion of resting CD4+ T cells. J Immunol 156, 1189-1195
111. Frangione B, Wisniewski T and Ghiso J (1994). Chaperoning Alzheimer's amyloids. Neurobiol aging 15, suppl 2, 97-99
112. Gallo G, Wisniewski T, Choi-Miura N, Ghiso J and Frangione B (1994). Potential role of apolipoprotein-E in fibrillogenesis. A m J Pathol 145, 526-530.
113. Zhong-Sheng J, Brecht WJ, Miranda D, Hussain MM, Innerarity TL and Mahley RW (1993). Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem 268, 10160-10167
114. Ihrcke NS, Wrenshall LE, Lidman BJ and Platt JL (1993). Role of heparan aulfate in immune system-blood vessel interactions. Immunol Today 14, 500-505
115. Templeton DM (1992). Proteoglycans in cell regulation.Crit Rev Clin Lab Sci 29, 141-184
116. Logan A, Berry M, Gonzalez AM, Frautschy SA, Sporn MB, Baird A (1994). Effects of transforming growth factor beta 1 on scar production in the injured central nervous system of the rat. Eur J Neurosci 6, 355-363
117. Westergren-Thorsson G, Hernaas J, Sarnstrand B, Oldberg A, Heinegard D, Malmstrom A (1993). Altered expression of small proteoglycans, collagen, and transforming growth factor-β1 in developing bleomycin-induced pulmonary fibrosis in rats. J Clin Invest 92, 632-637
118. Chao CC, Hu S, Kravitz FH, Tsang M, Anderson Wr, Peterson PK (1994). Transforming growth factor-beta protects human neurons against beta-amyloid-induced injury. Mol Chem Neuropathol 23, 159-178
119. Peress NS, Perillo E (1995). Differential expression of TGF-beta 1, 2 and 3 isotypes in Alzheimer's disease: a comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. J Neuropathol Exp Neurol 54, 802-811
120. Frautschy SA, Yang F, Calderón L, Cole GM (1996). Rodent models of Alzheimer's disease: rat Aβ infusion approaches to amyloid deposits. Neurobiol Aging 17, 311-321
121. Morita H, Schinzato T, Cai Z et al (1995). Basic fibroblast growth factor-heparan sulphate complex in the human dialysis-related amyloidosis. Virchovis Arch 427, 395-400
122. Uhlin-Hansen L, Yanagishita M (1993). Differential effect of Brefeldin A on the biosynthesis of heparan sulfate and chondroitin/dermatan sulfate proteoglycans in rat ovarian granulosa cells in culture. J Biol Chem 268, 17370-17376
123. Stenstad T, Husby G (1996). Brefeldin A inhibits experimentally induced AA amyloidosis. J Rheumatol 23, 93-100
124. Westermark P (1994). Amyloid and polypeptide hormones: what is their interrelationship?. Amyoid: Int J Exp Clin Invest 1, 47-60
125. Perlmutter LS, Myers MA and Barron E (1994). Vascular basement membran components and the lesions of Alzheimer's disease: light and electron microscopic analyses. Microscopy Res Tech 28, 204-215
126. Inoue S, Kisilevsky R (1996). A high resolution ultrastructural study of experimental murine AA amyloid. Lab Invest 74, 670-683
127. Snow AD, Sekiguchi R, Nichlin D, Fraser P, Kimata K, Mizutani A, Arai M, Schreier WA and Morgani DG (1994). An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposistion and persistance of fibrillar Aβ-amyloid in rat brain. Neuron 12, 219-234
128. Ohashi K, Hara M, Yanagishita M, Kawai R, Tachibana S, Ogura Y (1995). Proteoglycans in haemodialysis-related amyloidosis. Virchows Arch 427, 49-59
129. Ohishi, H., Skinner M, Sato-Araki N, Okuyama T, Gejyo F, Kimura A, Cohen AS, and Schmid K (1990). Glycosaminoglycan of the hemodialysis-associated carpal synovial amyloid and of amyloid-rich tissues and fibrils of heart, liver and spleen. Clin Chem 36, 88-91
130. Moss J, Shore I, Woodrow D (1994). AA glomerular amyloid. An ultrastructural immunogold study of the colocalization of heparan sulphate proteoglycan and P component with amyloid fibrils together with changes in distribution of type IV collagen and fibronectin. Histopathol 24, 427-435
131. Morita H, Shinzato T, David et al (1995). Glycosaminoglycans in dialysis-related amyloidosis. In: Maeda K, Shinzato T (eds): Dialysis-related amyloidosis. Contrib Nephrol, Basel, 112, 83-89
132. Nordvag BY. Molecular genetic studies of inherited transthyretin-related amyloidosis causing severe cardiac disease in a Danish family. Thesis: University of Trouso